Aurinia Pharmaceuticals Inc.
NASDAQ:AUPHBiotechnology
+$0.13 today
- Market cap
- $2.03B
- Beta
- 1.43
- P/E (TTM)
- 7.2
- EPS (TTM)
- $2.25
Volume 0.76M
Average 1.21M
AUPH Sales of Investments
Cash received from selling or redeeming investments.
Aurinia Pharmaceuticals Inc.NASDAQ: AUPH
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments dips below year-ago levels
Q2 FY2026 sales of investments of $99.03M fell 25.1% year over year, behind the +5.6% change in trailing-twelve-month sales of investments. Sequentially, it fell 9.1% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Sales of investments amounted to 174.6% of revenue in FY2025, down 74.4 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.1% toward the trailing-twelve-month pace of +5.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 494.13M USD
- Year-over-year change
- -15.6%
- 4-year CAGR
- +8.7%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 494.13M | -15.6% |
| FY2024 | 2024-12-31 | 585.42M | +10.6% |
| FY2023 | 2023-12-31 | 529.38M | +14.0% |
| FY2022 | 2022-12-31 | 464.32M | +31.0% |
| FY2021 | 2021-12-31 | 354.43M | — |
Sales of Investments vs competitors
How AUPH compares with its peers on the latest reported figures
- AUPH's LTM Jun 2026 sales of investments of $540.38M is the 2nd largest of the 10 companies compared; the peer median is $185.26M.
- Its year-over-year change of +5.6% is the 6th highest of 9, against a peer median of +42.0%.
- Sales of investments amounts to 173.5% of revenue for AUPH, versus a peer median of 4228.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $555.15M | +110.1% | +46.4% | 7504.0% |
| LTM Jun 2026 | $540.38M | +5.6% | +2.1% | 173.5% | |
| LTM Jun 2026 | $492.8M | +18.2% | +86.5% | — | |
| LTM Mar 2026 | $382.74M | +65.8% | +261.7% | — | |
| LTM Jun 2026 | $350M | -46.3% | — | — | |
| LTM Mar 2026 | $185.26M | +87.4% | — | — | |
| FY2025 | $150.75M | +1784.4% | — | 11166.7% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $94.1M | — | — | 941.0% |
| LTM Mar 2026 | $79.8M | -19.5% | -20.6% | 953.7% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $0 | -100.0% | — | — |
| Peer median (excluding AUPH) | $185.26M | +42.0% | +66.5% | 4228.9% | |
Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (180.97M) | (108.18M) | (78.02M) | 5.75M | 287.2M |
| Depreciation & Amortization | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (176.19M) |
| Stock-Based Compensation | 31.24M | 32.3M | 45.31M | 31.6M | 14.68M |
| Change in Working Capital | (21.63M) | (6.82M) | (5.61M) | 5.45M | (8.78M) |
| Accounts Receivables | (15.42M) | 1.93M | (10.61M) | (12.46M) | (4.91M) |
| Inventory | (5.64M) | (9.07M) | (15.87M) | 477K | (6.46M) |
| Accounts Payables | 4.08M | (792K) | 1.24M | 860K | (1.87M) |
| Other Working Capital | (4.65M) | 1.12M | 19.63M | 16.57M | 4.46M |
| Other Non-Cash Items | 10.9M | 462K | (6.79M) | (17.85M) | 9.49M |
| Operating Cash Flow | (157.69M) | (79.53M) | (33.46M) | 44.39M | 135.66M |
| Capital Expenditures | (1.5M) | (292K) | (718K) | (281K) | (252K) |
| Acquisitions (Net) | (1.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (438.96M) | (523.99M) | (523.5M) | (545.83M) | (526.65M) |
| Sales of Investments | 354.43M | 464.32M | 529.38M | 585.42M | 494.13M |
| Other Investing Activities | (16.63M) | (663K) | (11.86M) | (43K) | 0 |
| Investing Cash Flow | (103.87M) | (60.63M) | (6.71M) | 39.26M | (32.77M) |
| Debt Repayment | 0 | 0 | (10.03M) | (11.99M) | (13.14M) |
| Common Stock Issued | 196.74M | 0 | 0 | 0 | 14.95M |
| Common Stock Repurchased | 0 | 0 | 0 | (40.24M) | (98.16M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 24.37M | 2.43M | 4.9M | 3.14M | (9.76M) |
| Financing Cash Flow | 221.11M | 2.43M | (5.13M) | (49.09M) | (106.11M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (40.45M) | (137.73M) | (45.3M) | 34.56M | (3.22M) |
| Free Cash Flow | (159.19M) | (79.82M) | (34.18M) | 44.11M | 135.41M |
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
Intrinsic Alpha fair value
Locked
Current Price
$15.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.